

表3 病原性関連遺伝子検出用PCRプライマーセット

Primers	forward	reverse
gene	5' - 3'	5' - 3'
vvhA (Hill et al)	vvhA-sf CCGCGGTACAGGTGGCGC	vvhA-sr CGCCACCCACTTTCGGGCC
vuua:	common vuua-cf TTGAAAGTGGGTAAAGCAGG	vuua-cr CATCTGCATACTGTCAAAAATCG
	specific vuua-sf AGGTACCTTTCTTTAGGGGGCC	vuua-sr GATATGGTGAATAATCCTCCGGCC
vvpE:	common vvpE-cf ATATTGGGGTGAAGCGGCAGAG	vvpE-cr GTGGTCGGTTTGTGCCCCGCTTT
	specific vvpE-sf1 CCGTTCAAGCTCGTAGTCTTGC	vvpE-sr1 TAGCATTGGCATTGCTTCACTTGG
	vvpE-sf2 CCTCGGGAAGCAGGCCACCAAG	vvpE-sr2 CCACCGCCGTCGCAATGGGATCC
vpl:	common vpl-cf CCTATGTTGCTGTTGGTATCG	vpl-cr GCGTTAAAGATGTTGCCCTGTATC
	specific vpl-sf1 AGCTCTCTCCTGAAGCGGATCAC	vpl-sr CGCCCCCTGCGTCAAGTGTGTTG
	vpl-sf2 CACATCACAAAACGTGATTAG	
mshD:	common mshD-cf ACAACAGCAATTTTGATGGTGG	mshD-cr TTTCCACTAAGGTAATAAACCCAGC
	specific mshD-sf ACCAGTTTGTCTTTTCCCAATG	mshD-sr GTATTGACCGCGGTGTATTGCC
vvpD:	common vvpD-cf CGTTACAATACTACCCTTGGCT	vvpD-cr TCTCCGTAACCCATGCTTCTTT
	specific vvpD-sf TTGGAAGTTCGGTTATGCACCG	vvpD-sr TTGAGATACCAAGACATCAAGC
viuB:	common viuB-cf AAAGATTAGGTGAAGAATGA	viuB-cr CAATAAACACATAGCCCTTTGGC
	specific viuB-sf CAGACAATATCGTGGCGGGTG	viuB-sr AGCAGACAGCGAGGTGCGCTTTC
httpd	common httpd-cf GCATCGCTCGAAGAAGCTTGG	httpd-cr ATAGCGCTTTGAAAGTTACCTTC
	specific httpd-sf TCAGCACTTAAGCACGCATTAA	httpd-sr TGGTAAATCACGCAATCGAGA
wza:	common wza-cf CATCTGAAGCAGGTAACCTGGG	wza-cr AGTGCTTCCGTCAGGCTCATGCC
	specific wza-sf CAGAACTTGATGTGCAGATCGC	wza-sr TCGCCCGGCTCTAATAAACCGG
hupA:	common hupA-cf TGTTGCTTTTGAACCAAGATCC	hupA-cr TGGTCTCTGAAACCTTGGCT
	specific hupA-sf TTCAAAAGCACCGTATGACGAC	hupA-sr CTAATAAGTGGCTTCTAATTC
ela:	common ela-cf TTTACCAAAATGAATCTGGTGC	ela-cr GGTGATGATGCCACTGTGTGAT
	specific ela-sf AATCGCGGCAATTCGAAATGG	ela-sr GCGGATGCCGTTTGAGTTTGGC
mntH:	common mnt-cf ACCTCTACAAAAGTCGACATGGCG	mnt-cr AGAATAATGCTATTCACTAAACC
	specific mnt-sf CTCTATTTCTACTCAAGFACCC	mnt-sr TACCTAAGTCCCTCTAGCTAAC

表4 血清型参照株における病原性関連遺伝子PCR

O-serogroup	reference strain	由来	PCR													
			wvh	vuua	vypE	vpl	wza	nshD	vypD	ela	viuB	4-hppd	hupA	mntH		
O1 (type strain)	ATCC27562	血液 (CDC)	+	+	+	+	+	+	+	+	+	+	+	+	+	-
O1 (H-血清作成用)	459-95	エビ (デンマーク)	+	-	+	+	+	-	+	+	+	-	-	-	+	+
O2	D3894	血液 (CDC)	+	-	+	+	-	+	+	+	+	-	-	+	+	+
O3	E240	血液 (CDC)	+	(+)	+	+	+	+	+	+	+	+	+	+	+	+
O3	E240-1(vvh -)		-	(+)	+	+	+	+	+	+	+	+	+	+	+	+
O4a	1115-80	血液 (東大病院)	+	(+)	+	+	+	+	+	+	+	+	+	+	+	+
O5	E571	血液 (CDC)	+	(+)	+	+	+	+	+	+	+	+	+	+	+	+
O6	91-81	血液 (京都市)	+	+	+	+	+	+	+	+	+	+	+	+	+	+
O7	1338-80	アサリ (神戸市)	+	+	+	+	+	+	+	+	+	+	+	+	+	+
O8	191-87	カキ (韓国)	+	-	+	+	-	+	+	+	+	+	+	+	+	+
O9	189-87	カキ (韓国)	+	+	+	+	+	+	+	+	+	+	+	+	+	+
O10	586-88	エビ (インド)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O11	705-88	血液 (韓国)	+	-	+	+	+	+	+	+	+	+	+	+	+	+
O12	371-89	血液 (タイ)	+	+	+	+	+	+	+	+	+	+	+	+	+	+
O13	W-vv5	膿 (韓国)	+	-	+	+	+	+	+	+	+	+	+	+	+	+
O14	C84-7-4-vv1	血液 (韓国)	+	+	+	+	+	+	+	+	+	+	+	+	+	+
O15	889-89	ウナギ (ノルウェー)	+	+	+	+	+	+	+	+	+	+	+	+	+	-
O16	611-95	海水 (ドイツ)	+	+	+	+	-	+	+	+	+	+	+	+	+	-

(+) はバンドは検出されたものの、サイズが異なっていたもの

表5 患者由来株、環境由来株の病原性関連遺伝子PCR

Vibrio vulnificus 患者由来株														
PCR														
O-serogroup	No. of isolates	(%)	vvh	vuua	vvpE	vpl	wza	mshD	vvpD	ela	viuB	4-tppd	hupA	mntH
O1	6	26.1%	6/6	1/6	6/6	6/6	6/6	6/6	6/6	6/6	6/6	2/6	0/6	5/6
O4	12	52.2%	12/12	2/12	12/12	12/12	12/12	12/12	12/12	12/12	12/12	5/12	7/12	6/12
O5	1	4.3%	1/1	0/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	0/1	1/1
O6	1	4.3%	1/1	0/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	0/1	1/1	1/1
O7	3	13.0%	3/3	0/3	3/3	3/3	3/3	2/3	3/3	3/3	3/3	3/3	3/3	(3)/3
Total	23	100.0%	23/23	3/23	23/23	23/23	23/23	22/23	23/23	23/23	23/23	11/23	11/23	16/23
(positive%)			(100%)	(13%)	(100%)	(100%)	(100%)	(96%)	(100%)	(100%)	(100%)	(48%)	(48%)	(70%)

環境由来株														
PCR														
O-serogroup	No. of isolates	(%)	vvh	vuua	vvpE	vpl	wza	mshD	vvpD	cla	viuB	4-tppd	hupA	mntH
O1	6	28.6%	6/6	6/6	3/6	6/6	6/6	6/6	6/6	6/6	6/6	0/6	0/6	6/6
O3	1	4.8%	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	0/1	1/1
O4	6	28.6%	6/6	(4)/6	6/6	6/6	5/6	6/6	6/6	6/6	6/6	5/6	2/6	6/6
O6	2	9.5%	2/2	1/2	2/2	2/2	2/2	2/2	2/2	2/2	2/2	0/2	2/2	2/2
O8	2	9.5%	2/2	2/2	2/2	2/2	0/2	2/2	2/2	2/2	2/2	0/2	2/2	2/2
O14	1	4.8%	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	0/1	1/1	1/1
O16	2	9.5%	2/2	2/2	2/2	2/2	2/2	2/2	2/2	2/2	2/2	0/2	2/2	2/2
R	1	4.8%	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	1/1	0/1	0/1	1/1
Total	21	100.0%	21/21	18/21	18/21	21/21	18/21	21/21	21/21	21/21	21/21	6/21	9/21	21/21
(positive%)			(100%)	(86%)	(86%)	(100%)	(86%)	(100%)	(100%)	(100%)	(100%)	(29%)	(43%)	(100%)

() 内はバンドは検出されたものの、サイズが異なっていたものが含まれている

Vibrio vulnificus septicaemia in Japan: An estimated number of infections and physicians'

knowledge of the syndrome.

K.OSAKA¹, M.KOMATSUZAKI^{2,3}, H.TAKAHASHI¹, S.SAKANO⁴ and N.OKABE¹.

¹ *Infectious Disease Surveillance Centre, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.*

² *Field Epidemiology Training Program, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.*

³ *Department of Infection Control, Jikei University School of Medicine, Tokyo 105-8471, Japan*

⁴ *Department of Public Health, School of Medicine, Hirosaki University, Hirosaki, 036-8562, Japan*

Key words: *Vibrio vulnificus*, septicemia, incidence and physicians' knowledge

Heading: *V.vulnificus* septicemia in Japan

Corresponding author:

Ken OSAKA MD, MPH, PhD

Infectious Disease Surveillance Centre, National Institute of Infectious Diseases

1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

Tel:81-3-5285-1111 Fax:81-3-5285-11129

E-mail: kosaka@nih.go.jp

Abstract

Questionnaire surveys were implemented to study the incidence and physician's knowledge of *Vibrio vulnificus* infections in Japan. Registered emergency physicians were selected by stratified random sampling for a questionnaire survey. A total of 235 out of 386 physicians (61%) responded to the questionnaire and 12 *V. vulnificus* septicaemia cases were reported from 10 respondents. The annual estimated number of *V. vulnificus* septicaemia was calculated as 425 (95% CI: 238 – 752). The study also revealed that only 15.7% (95% CI =11.3 - 21.0) of responding physicians had a basic knowledge of *V. vulnificus* infection. Education for both physicians and people at high-risk group of developing the infection (e.g. immunocompromised, chronic liver disease) will be necessary for the prevention, early diagnosis and appropriate treatment of the disease.

Vibrio vulnificus grows in warm estuaries and seawater. It can cause septicaemia, which is life-threatening, especially for the immunocompromised or people with chronic liver disease. The infection has been a leading cause of seafood-related deaths [1]. The food implicated in most reported cases has been raw oysters. Illness occurs after ingestion of the seafood or exposure to estuarine water; oysters harvested in warmer months are major vehicles of the disease in the USA [2]. The clinical course is very acute and severe and one third of the patients with *V.vulnificus* infection go into endotoxic shock in a few days with up to a 50% case fatality rate [3, 4]. Despite the limited data available on the epidemiology of the infection, approximately 70-90 cases of *V.vulnificus* infections are annually reported in USA [5] and 40-50 septicaemia cases are reported in South Korea [6].

Japan is the largest importer and biggest consumer of seafood in the world [7]. Many types of seafood, especially oysters, shrimp and the other crustaceans are often eaten raw or undercooked. Most Japanese people may therefore be at high risk for food-borne microbial infections from seafood. There were more than 400 outbreaks reported each year due to *Vibrio parahaemolyticus* involving 3,000-9,000 people and most of them were associated with consumption of raw or undercooked seafood [8]. Furthermore, more than two million people are estimated to suffer from chronic liver diseases, an important risk factor for *V.vulnificus* infections [9]. Sampling tests showed about 30% of local oysters (species not suitable for human consumption) were

contaminated with *V.vulnificus* [10].

As a result of risk behaviour and host factors, 7 cases of *V. vulnificus* infection with 3 fatalities were identified in Kumamoto prefecture during the summer season (June 29- July 18). Most cases were associated with consumption of uncooked Japanese mantis shrimp (*Oratosquilla oratoria*) [11].

However, the overall public health impact of *V. vulnificus* infections has not been evaluated in Japan. The infection is not widely recognized; the infection has not been included in the national notifiable diseases list. From 1978 through 1999, only 93 *V. vulnificus* infections were reported in Japanese scientific journals [12]. To assess the public health impact of *V. vulnificus* infections, we estimated its annual number of septicaemias and examined the knowledge of physicians of the disease by means of a questionnaire survey.

We developed a self-administered survey that included questions about working place (i.e. Prefecture), clinical specialties, years since medical school graduation, number of patients diagnosed with *V. vulnificus* infections during the year 2000, and basic knowledge of *V. vulnificus* infections (i.e. mode of transmission and clinical symptoms). Physicians in emergency rooms and intensive care units were specifically targeted to find emergency cases. The Japanese Association for Acute Medicine (JAAM) is the largest medical association for emergency medicine in Japan with a membership of 8,324 physicians, 3.3% of all physicians in Japan. In addition to the

emergency room, JAAM members serve in other specialties such as internal medicine and surgery. After implementing a pilot study, 386 member physicians from 323 facilities were selected by prefecture-stratified random sampling using the year 2000 JAAM membership directory. Questionnaires were mailed to the physicians' working places in February 2001, and responders were requested to reply anonymously by the end of March 2001. A follow up letter was sent to all targeted physicians. For statistical analyses, the chi-square test was used using EPINFO 6.04b software.

Of 386 JAAM members selected, 235 (61%) responded to the questionnaire. Twelve *V. vulnificus* septicaemia cases were reported from 10 respondents. Two cases were reported from each of three prefectures (Tokyo, Fukuoka, and Saga); the other six cases were from Hokkaido, Aomori, Ehime, Kochi, Nagasaki, and Kumamoto (Figure 1). Except for the Hokkaido case, the other 11 cases were from locations where *V. vulnificus* infections had been previously reported. The total annual number of cases was estimated by the following equation:

$$N = \text{Reported No. of cases from the survey} \times \frac{\text{Total number of JAAM members}}{\text{Number of responding physicians}}$$

Using the above survey data, the annual number of *V. vulnificus* septicaemia cases in Japan was estimated as 425 (95% CI: 238 – 752)

Among the 235 respondents, 198 (85.3%) stated that they had no knowledge of *V.*

vulnificus infections. The percentage of respondents who had appropriate knowledge of the infection was significantly higher in the western region (23.9% 95%CI [15.6, 33.9]) than the eastern region (10.1% 95%CI [5.7, 16.4]) ($P<0.05$), and it was higher in emergency physicians (28.6%) than surgeons (3.2%)($P<0.05$). On the other hand, knowledge was not associated with number of years since medical school graduation ($P>0.44$).

This was the first epidemiological survey to estimate the disease burden of *V. vulnificus* infections in Japan. In this study, we targeted only registered JAAM members. There was a possibility of underestimating the number of patients. Patients may have failed to see doctors and they might have been treated in departments other than those of emergency physicians. Furthermore, emergency room physicians might have treated affected patients without confirming the causative pathogen.

When we compared our estimated number with the other countries (South Korea and USA), our estimate was the highest of the three. Although the USA has 2.5 times more people than Japan, the frequency of eating raw or undercooked seafood is relatively low in the US: oysters are main seafood consumed raw. South Korea has approximately one third the population of Japan but is located in a colder climate. The frequency and degree of contamination of seafood with *V. vulnificus* may be higher in Japan, because the seawater temperature influences the proliferation of the bacteria. Considering that Korean data is also based on a passive reporting system, it seems

reasonable that Japan has the highest number of *V. vulnificus* septicaemia.

This study also demonstrated that the awareness of *V. vulnificus* infections among Japanese physicians was low. Emergency room physicians and those who work in the western region of the country had more knowledge of the problem, but the length of a physician's career did not appear to improve knowledge. These results indicate that those who are aware of *V. vulnificus* infections probably gained their knowledge through clinical experience or other sources rather than medical school education. Education about *V. vulnificus* infections should be addressed, not only to emergency room physicians, but also to general physicians who can urge high risk patients.(e.g. those suffering from chronic liver diseases or the immunocompromised) to avoid eating raw seafood. This study is the first step to estimate the public health impact of *V. vulnificus* infections in Japan. Inter-disciplinary interventions involving physicians, microbiologists, public health professionals, and high-risk populations and their families are needed.

Acknowledgements

We greatly appreciate Dr. John Kobayashi and Dr. Michael Kramer for advice on the study. This study was planned and developed with support of the Japanese Ministry of Health, Labour, and Welfare scientific research grant on emerging and re-emerging infectious diseases.

References

1. Potasman I, Paz A, Odeh M. Infectious outbreaks associated with bivalve shellfish consumption: a worldwide perspective. *Clin Infect Dis*. 2002; 35: 921-8.
2. Shapiro RL, Altekrose S, Hutwagner L, et al. The role of Gulf Coast oysters harvested in warmer months in *Vibrio vulnificus* infections in the United States, 1988-1996. *Vibrio Working Group. J Infect Dis*. 1998; 178: 752-9.
3. Klontz KC, Lieb S, Schreiber M, Janowski HT, Baldy LM, Gunn RA. Syndromes of *Vibrio vulnificus* infections. Clinical and epidemiologic features in Florida cases, 1981-1987. *Ann Intern Med* 1988; 109: 318-23.
4. Tacket CO, Brenner F and Blake PA. Clinical features and an epidemiological study of *Vibrio vulnificus* infections. *J Infect Dis* 1984; 149: 558-61.
5. Centers for Disease Control and Preventions. Summary of human isolates reported to *Vibrio* Surveillance System, 2000-2001.
http://www.cdc.gov/ncidod/dbmd/diseaseinfo/files/CSTE_Vibrio_2000.pdf
6. Ministry of Health and Welfare, republic of Korea. Communicable Diseases Monthly Report 2002; 13: 14.
7. Food and Agriculture Organization of the United Nations. Fishery Trade Flow (1995-1997). FAO 2000. Rome.

8. World Health Organization. *Vibrio parahaemolyticus*, Japan, 1996-1998. Weekly Epidemiological Record 1999; 29: 361-2
9. Tanaka J. Estimation of HBV and/or HCV carrier populations in Hiroshima prefecture and in Japan based on the data from voluntary blood donors. Nippon Koshu Eisei Zasshi. 1997; 44: 788-96.
10. Oonaka K, Furuhata K, Iguchi K, Hara M, Fukuyama M. Basic studies on *Vibrio vulnificus* infection: isolation of *V. vulnificus* from sea water, sea mud, and oysters. Kansenshogaku Zasshi. 2002; 76: 528-35.
11. National Institute of Infectious Disease, Japan. Outbreak of *Vibrio vulnificus* infection in Kumamoto prefecture. Infect Agent Surv Rep 2001; 46: 249.
12. Yasuko K, Masayoshi J, Keiichi N, Tomomichi Ono. *Vibrio vulnificus* infections. Nihonhifukagakkaizasshi 1999;109 :875-84.[Japanese]

Legend of figures

Fig.1 A map of Japan shows the number and distribution of *V.vulnificus* septicemias cases reported in each prefecture.




Figure 1